Barometer Capital Management Inc. Purchases 39,300 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Barometer Capital Management Inc. raised its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 569.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,200 shares of the company’s stock after acquiring an additional 39,300 shares during the quarter. Barometer Capital Management Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $1,042,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. CIBC Private Wealth Group LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares during the period. Arax Advisory Partners grew its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth approximately $58,000. Finally, Group One Trading LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at approximately $74,000. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.5%

Shares of FMS stock opened at $24.68 on Wednesday. The firm has a 50 day moving average price of $22.83 and a two-hundred day moving average price of $22.86. The company has a quick ratio of 0.86, a current ratio of 1.20 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $13.25 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 4.34 and a beta of 0.78. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $27.64.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The company had revenue of $5.34 billion during the quarter. As a group, analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently declared an annual dividend, which was paid on Monday, June 8th. Investors of record on Friday, May 22nd were paid a $0.8716 dividend. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date was Friday, May 22nd. This represents a yield of 402.0%. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is presently 32.11%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on FMS shares. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research report on Friday, May 8th. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Sanford C. Bernstein initiated coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, July 16th. They set a “market perform” rating for the company. Finally, Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Six investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.